Tesamorelin 10mg Metabolism
Stabilised GHRH analogue. 99.5% purity.
- Certificate of analysis
- In stock in France
Ordered with its water: shipped in a magnetic box
-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees
No card: each delivery is paid in Bitcoin (extra -5%) or by bank transfer
Your complete kit
The vial alone cannot be used as is. Add what you need to prepare it:
Frequently bought together
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
Protocol and preparation
| Water added | Concentration | Reading marker |
|---|---|---|
| 1 ml | 10 mg/ml | 10 UI = 1 mg |
| 2 ml | 5 mg/ml | 40 UI = 2 mg |
The volume of water does not change the product, only its concentration. Add the water slowly along the vial wall, then swirl without shaking.
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Add gently against the vial wall (avoid a direct jet on the powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
I open the dilution calculator- The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
- The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
Durée de protocole: les essais pivotaux ont utilisé des cycles de 26 semaines (phase 3 initiale) puis 52 semaines (extension). En recherche exploratoire, des cycles de 12-26 semaines sont typiques. Au-delà de 12 mois, les données de tolérance sont limitées.
Technical data
- Reconstitution
- 2 ml d'eau → 5 mg/ml. 20 UI = 1 mg ; 40 UI = 2 mg.
- Peptide sequence
- trans-3-hexénoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5135.78 g/mol
- CAS number
- 218949-48-5
- Physical form
- Poudre lyophilisée
- Recommended solubility
- Eau bactériostatique, NaCl 0,9%
- Storage conditions
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Use
- Research reagent, in vitro only (RUO)
Mechanism of action
Tesamorelin is a complete synthetic analog of native human GHRH (44 amino acids), modified by adding a trans-3-hexenoic acid group at the N-terminal position. This chemical modification, developed by Theratechnologies, protects the peptide from degradation by dipeptidyl peptidase IV (DPP-IV), the main enzyme responsible for the short half-life of native GHRH. Total molecular weight ~5196 Da, chemical formula C221H366N72O67S.
The pulsatile GH secretion induced by Tesamorelin remains physiological (preservation of endogenous pulses), distinguishing this approach from exogenous recombinant GH administration producing supra-physiological non-pulsatile levels. IGF-1 increases 80-100% from baseline after 26 weeks, a value comparable to CJC-1295 DAC trials but with daily rather than weekly kinetics.
Studies and references
On fundamental pharmacology, Dhillo et al. (Endocrinology 2003) had previously characterized the GHRH-R binding profile and pharmacokinetics compared to native GHRH, demonstrating extended duration of action linked to DPP-IV resistance.
Corpus limitationsThe vast majority of clinical data concerns the HIV population with lipodystrophy. Data in healthy subjects or other metabolic indications are more limited. The 2014 EMA refusal reflects uncertainties about long-term benefit-risk in the general population. Tesamorelin remains strictly a research peptide outside the approved HIV indication.
Frequently asked questions
What is the delivery lead time in Europe?
Read before you orderGH secretagogues in research: CJC-1295, Ipamorelin, GHRP-2/6, hexarelin, MK-677 — mechanisms, synergies and preclinical protocolsComprehensive scientific overview of growth hormone secretagogues: GHRH analogues (sermorelin, CJC-1295, tesamorelin), peptide GHRPs (Ipamorelin, GHRP-2/6, hexarelin), non-peptide GHS-R1a agonist (MK-677). Pharmacology, GHRH+GHRP synergy, rodent models, analytical QC, RUO framework.Read the article Also read:GHRH vs GHRP: the 2026 research peptide comparison for growth hormone secretagogues
